News

Data from a secondary analysis of a randomized controlled trial provide an overview of the cardiovascular safety of trastuzumab biosimilar SB3 compared to the reference agent.

Leveraging data from the UK Biobank study, a new study offers insight into the risk of new-onset heart failure based on female reproductive risk factors among a cohort more than 220,000 women.

The study addresses the need for consistent diagnostic practices related to unintentional weight loss in primary care patients as practices vary widely among physicians.

At ARVO 2023, Goldberg discusses how dual Ang-2/VEGF inhibition can provide greater vascular stability, which may contribute to faster fluid resolution and extended durability with faricimab treatment.

As previous studies have shown slow uptake of biosimilars, Ross Maltz, MD, and his team wanted to get a better understanding of this issue using a survey focused on pediatric gastroenterologists.

A personalized treat-and-extend–based regimen presented at ARVO 2023 suggested the long-term potential of faricimab to reduce the treatment burden for patients with DME.

Sleep duration and daytime napping are not strongly linked to dementia risk, although there may be a small increase in risk associated with short sleep duration.

Recent data showed that a new HS-IGA tool for hidradenitis suppurativa addressed several concerns of prior tools but also maintained certain limitations.

An analysis of data from more than 119,000 pregnancies suggests women with prenatal depression were at increased risk for multiple forms of cardiovascular disease within the first 2 years following delivery relative to their counterparts without prenatal depression.

IgE-mediated children with cow’s milk allergies switching from amino acid-based formula to a new formula showed strong tolerance and better acquisition of immune tolerance, suggesting other studies combining treatments may be useful.

Patients receiving tocilizumab and LZM008 showed comparable pharmacokinetic properties after a single intravenous dose.

Investigators designed an algorithm with high diagnostic accuracy to reduce unnecessary polysomnography examinations and optimize the identification of participants with iRBD.

Women with obstructive sleep apnea show increased extracellular water and decreased intracellular water and phase angle compared with men before treatment with CPAP.

RBX2660 and Vowst are now both approved for the prevention of recurrent C. difficile infections.

New data indicates that unawareness of declines in memory was more associated with Alzheimer’s than awareness, providing physicians with a greater understanding of cognitive decline.

Vowst represents the first oral live microbiota therapeutic approved for recurrent C. difficile infections.

A study of more than 3000 Mediterranean adults is shedding light on the impact of longer midday naps on risk of metabolic syndrome, fasting glucose, and diastolic blood pressure.

In this interview, Bhutani discussed a recent peer-reviewed study which highlighted concerns over skin cancer dangers for psoriasis patients treated with methotrexate.

Data from the SURMOUNT-2 trial demonstrate use of tirzepatide 10 mg and 15 mg were associated with mean weight reductions of 13.4% and 15.7%, respectively, with more than 80% of tirzepatide users achieving a body weight reduction of 5% or greater.

The treatment is the second live microbiota therapeutic approved by the FDA, coming just a few months after the agency approved RBX2660 for recurrent C. difficile infections.

The serum glycated hemoglobin levels and the incidence of thyroid cancer in patients with type 2 diabetes in patients with type 2 diabetes were significantly higher in the observation group when compared with the control group.

Data reveal 42 SNPs associated with eosinophil counts, 18 SNPs with airway obstruction, and 21 SNPs with atopy.

An analysis of the TENAYA/LUCERNE presented at ARVO 2023 suggests faricimab more rapidly improved anatomic outcomes in patients with nAMD compared to aflibercept.

The research method, which provides better context into patient and caregiver perspective on the field, has increased nearly two-fold in prevalence since 2020.

The results also show 10.3% of the patients with celiac disease that was histopathological confirmed were seronegative to Anti-TtG-IgA, but seropositive to anti-DGP-IgA and/or Anti-DGP-IgG.

An analysis of the phase 2/3 PHOTON trial suggested the majority of patients with DME who received aflibercept 8 mg maintained 12- or 16-week dosing intervals.

A prespecified analysis of the DELIVER trial provides insight into the effects of dapagliflozin use on total heart failure events in patients with mildly reduced or preserved ejection fraction.